Boston Scientific (BSX) said Friday that it completed the acquisition of Axonics (AXNX), a medical technology company specializing in devices for urinary and bowel dysfunction.
The company said the deal, which has an equity value of $3.7 billion and an enterprise value of $3.3 billion, is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and become accretive afterward.
Boston Scientific also said that the deal is slated to be less accretive on a GAAP basis due to amortization and acquisition-related costs.
Price: 87.12, Change: -0.47, Percent Change: -0.54
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。